共 206 条
[1]
Moise-Broder PA(2004)Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections Clin Pharmacokinet 43 925-942
[2]
Forrest A(2006)The pharmacokinetic and pharmacodynamic properties of vancomycin Clin Infect Dis 42 S35-39
[3]
Birmingham MC(2001)Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus Emerg Infect Dis 7 327-332
[4]
Schentag JJ(2011)Clinical practice guidelines by the clinically infected diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary Clin Infect Dis 52 285-292
[5]
Rybak MJ(2009)Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the clinically infected diseases society of America, and the society of clinically infected diseases pharmacists Am J Health Syst Pharm 66 82-98
[6]
Tenover FC(2006)High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 166 2138-2144
[7]
Biddle JW(2007)Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections Expert Rev Anti Infect Ther 5 255-270
[8]
Lancaster MV(2009)Vancomycin therapeutic guidelines: a summary of consensus recommendations from the clinically infected diseases society of America, the American society of health-system pharmacists, and the society of clinically infected diseases pharmacists Clin Infect Dis 49 325-327
[9]
Liu C(2012)Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis J Antimicrob Chemother 67 17-24
[10]
Bayer A(2011)Continuous and intermittent infusion of vancomycin equally effective: review of the literature Ned Tijdschr Geneeskd 155 A2667-451